The combined inhibition of MDM2 and STAT3 presents a promising therapeutic strategy that warrants continued exploration in both ALL and other cancers characterized by p53 deficiency or STAT3 dysregulation. Here, MDM2 is linked to acute lymphoblastic leukemia.